Yusuke Nakamura to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Yusuke Nakamura has written about Neoplasm Recurrence, Local.
Connection Strength
0.683
-
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
Score: 0.275
-
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci. 2017 01; 38(1):15-24.
Score: 0.093
-
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients. Int J Cancer. 2014 Jan 15; 134(2):352-66.
Score: 0.076
-
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
Score: 0.075
-
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet. 2013 Jun; 58(6):327-33.
Score: 0.073
-
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
Score: 0.028
-
Recurrence in regional pulmonary lymph nodes after surgery for isolated pulmonary metastasis from hepatocellular carcinoma. Gen Thorac Cardiovasc Surg. 2016 Jun; 64(6):351-4.
Score: 0.020
-
Colorectal cancer metastasis to the thyroid. Osaka City Med J. 2012 Dec; 58(2):67-75.
Score: 0.018
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.013
-
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008 May; 99(5):995-9.
Score: 0.013